Biotech
ClarisBio Raises $118M for Eye Disease Drug
ClarisBio, a new biotech company, secured $118 million to develop a treatment for a rare corneal disease.
A new company, ClarisBio, is making big moves in biotech. It just raised $118 million. This money will help the company create a new drug. The drug treats a rare eye disease. This condition affects the front of the eye.
Novo Holdings supports ClarisBio. Novo Holdings led the funding round. This significant investment shows trust in ClarisBio's mission. The company focuses on corneal diseases. These conditions often have few treatment options.
ClarisBio's work could change many lives. Their new drug may offer hope to those with unmet medical needs. The company now moves closer to bringing its treatment to patients.
Source: FierceBiotech
#Biotech#Funding#Corneal Disease#Novo Holdings
More from Biotech
